These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 36851662)

  • 1. Longitudinal IgA and IgG Response, and ACE2 Binding Blockade, to Full-Length SARS-CoV-2 Spike Protein Variants in a Population of Black PLWH Vaccinated with ChAdOx1 nCoV-19.
    Smith M; Kwatra G; Izu A; Nel A; Cutland C; Ahmed K; Baillie V; Barnabas S; Bhorat Q; Briner C; Lazarus E; Dheda K; Fairlie L; Koen A; Madhi S; Blackburn JM
    Viruses; 2023 Feb; 15(2):. PubMed ID: 36851662
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Profile of humoral and cellular immune responses to single doses of BNT162b2 or ChAdOx1 nCoV-19 vaccines in residents and staff within residential care homes (VIVALDI): an observational study.
    Tut G; Lancaster T; Krutikov M; Sylla P; Bone D; Kaur N; Spalkova E; Bentley C; Amin U; Jadir AT; Hulme S; Butler MS; Ayodele M; Bruton R; Shrotri M; Azmi B; Fuller C; Irwin-Singer A; Hayward A; Copas A; Shallcross L; Moss P
    Lancet Healthy Longev; 2021 Sep; 2(9):e544-e553. PubMed ID: 34430954
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Kinetics of the Antibody Response to Boostering With Three Different Vaccines Against SARS-CoV-2.
    Markewitz R; Juhl D; Pauli D; Görg S; Junker R; Rupp J; Engel S; Steinhagen K; Herbst V; Zapf D; Krüger C; Brockmann C; Leypoldt F; Dargvainiene J; Schomburg B; Sharifzadeh S; Nejad LS; Wandinger KP; Ziemann M
    Front Immunol; 2022; 13():811020. PubMed ID: 35126395
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IgG antibody levels against the SARS-CoV-2 spike protein in mother-child dyads after COVID-19 vaccination.
    Muñoz-Gómez MJ; Martin-Vicente M; Vigil-Vazquez S; Carrasco I; Lobo AH; Mas V; Vázquez M; Manzanares A; Cano O; Zamora C; Alonso R; Sepulveda-Crespo D; Tarancon-Diez L; Muñoz-Fernández MÁ; Muñoz-Chapuli M; Resino S; Navarro ML; Martinez I
    Infection; 2024 Jun; 52(3):813-824. PubMed ID: 37898587
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interdependencies of cellular and humoral immune responses in heterologous and homologous SARS-CoV-2 vaccination.
    Hollstein MM; Münsterkötter L; Schön MP; Bergmann A; Husar TM; Abratis A; Eidizadeh A; Schaffrinski M; Zachmann K; Schmitz A; Holsapple JS; Stanisz-Bogeski H; Schanz J; Fischer A; Groß U; Leha A; Zautner AE; Schnelle M; Erpenbeck L
    Allergy; 2022 Aug; 77(8):2381-2392. PubMed ID: 35124800
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Despite delayed kinetics, people living with HIV achieve equivalent antibody function after SARS-CoV-2 infection or vaccination.
    Motsoeneng BM; Manamela NP; Kaldine H; Kgagudi P; Hermanus T; Ayres F; Makhado Z; Moyo-Gwete T; van der Mescht MA; Abdullah F; Boswell MT; Ueckermann V; Rossouw TM; Madhi SA; Moore PL; Richardson SI
    Front Immunol; 2023; 14():1231276. PubMed ID: 37600825
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibody responses after a single dose of ChAdOx1 nCoV-19 vaccine in healthcare workers previously infected with SARS-CoV-2.
    Havervall S; Marking U; Greilert-Norin N; Ng H; Gordon M; Salomonsson AC; Hellström C; Pin E; Blom K; Mangsbo S; Phillipson M; Klingström J; Hober S; Nilsson P; Åberg M; Thålin C
    EBioMedicine; 2021 Aug; 70():103523. PubMed ID: 34391088
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-SARS-CoV-2 IgA and IgG in human milk after vaccination is dependent on vaccine type and previous SARS-CoV-2 exposure: a longitudinal study.
    Selma-Royo M; Bäuerl C; Mena-Tudela D; Aguilar-Camprubí L; Pérez-Cano FJ; Parra-Llorca A; Lerin C; Martínez-Costa C; Collado MC
    Genome Med; 2022 Apr; 14(1):42. PubMed ID: 35449030
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlation of SARS-CoV-2 Viral Neutralizing Antibody Titers with Anti-Spike Antibodies and ACE-2 Inhibition among Vaccinated Individuals.
    Grunau B; Prusinkiewicz M; Asamoah-Boaheng M; Golding L; Lavoie PM; Petric M; Levett PN; Haig S; Barakauskas V; Karim ME; Jassem AN; Drews SJ; Sediqi S; Goldfarb DM
    Microbiol Spectr; 2022 Oct; 10(5):e0131522. PubMed ID: 36121252
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study.
    Hillus D; Schwarz T; Tober-Lau P; Vanshylla K; Hastor H; Thibeault C; Jentzsch S; Helbig ET; Lippert LJ; Tscheak P; Schmidt ML; Riege J; Solarek A; von Kalle C; Dang-Heine C; Gruell H; Kopankiewicz P; Suttorp N; Drosten C; Bias H; Seybold J; ; Klein F; Kurth F; Corman VM; Sander LE
    Lancet Respir Med; 2021 Nov; 9(11):1255-1265. PubMed ID: 34391547
    [TBL] [Abstract][Full Text] [Related]  

  • 11. mRNA vaccination drives differential mucosal neutralizing antibody profiles in naïve and SARS-CoV-2 previously-infected individuals.
    Longet S; Hargreaves A; Healy S; Brown R; Hornsby HR; Meardon N; Tipton T; Barnes E; Dunachie S; Duncan CJA; Klenerman P; Richter A; Turtle L; de Silva TI; Carroll MW
    Front Immunol; 2022; 13():953949. PubMed ID: 36159846
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characteristics associated with serological COVID-19 vaccine response and durability in an older population with significant comorbidity: the Danish Nationwide ENFORCE Study.
    Søgaard OS; Reekie J; Johansen IS; Nielsen H; Benfield T; Wiese L; Stærke NB; Iversen K; Fogh K; Bodilsen J; Iversen M; Knudsen LS; Klastrup V; Larsen FD; Andersen SD; Hvidt AK; Andreasen SR; Madsen LW; Lindvig SO; Øvrehus A; Ostrowski SR; Abildgaard C; Matthews C; Jensen TO; Raben D; Erikstrup C; Fischer TK; Tolstrup M; Østergaard L; Lundgren J;
    Clin Microbiol Infect; 2022 Aug; 28(8):1126-1133. PubMed ID: 35283313
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibody profile in post-vaccinated & SARS-CoV-2 infected individuals.
    Patil R; Shanbhag S; Shankarkumar A; Madkaikar M
    Indian J Med Res; 2022; 155(5&6):538-545. PubMed ID: 36124500
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Persistent and robust antibody responses to ChAdOx1-S Oxford-AstraZeneca (ChAdOx1-S, Covishield) SARS-CoV-2 vaccine observed in Ugandans across varied baseline immune profiles.
    Serwanga J; Oluka GK; Baine C; Ankunda V; Sembera J; Kato L; Katende JS; Odoch G; Auma BO; Gombe B; ; Musenero M; Kaleebu P
    PLoS One; 2024; 19(7):e0303113. PubMed ID: 39074077
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SARS-CoV-2 RBD-Specific Antibodies Induced Early in the Pandemic by Natural Infection and Vaccination Display Cross-Variant Binding and Inhibition.
    Walker MR; Podlekareva D; Johnsen S; Leerhøy B; Fougeroux C; Søgaard M; Salanti A; Ditlev SB; Barfod L
    Viruses; 2022 Aug; 14(9):. PubMed ID: 36146667
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A study on seroconversion following first & second doses of ChAdOx1 nCoV-19 vaccine in Central Kerala.
    Varghese SM; Mateethra GC; George G; Chandran VS; John GM; Varghese LT; Mammen NK; Vinayak V
    Indian J Med Res; 2022; 155(5&6):499-504. PubMed ID: 36348597
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dynamics of SARS-CoV-2 Spike-IgG throughout Three COVID-19 Vaccination Regimens: A 21-Month Longitudinal Study of 82 Norwegian Healthcare Workers.
    Augustinussen MH; Tylden GD; Rinaldo CH
    Viruses; 2023 Feb; 15(3):. PubMed ID: 36992328
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sub-optimal neutralisation of omicron (B.1.1.529) variant by antibodies induced by vaccine alone or SARS-CoV-2 Infection plus vaccine (hybrid immunity) post 6-months.
    Medigeshi GR; Batra G; Murugesan DR; Thiruvengadam R; Chattopadhyay S; Das B; Gosain M; Ayushi ; Singh J; Anbalagan A; Shaman H; Pargai K; Mehdi F; Das SJ; Kahlon N; Singh S; Kshetrapal P; Wadhwa N; Pandey AK; Bhatnagar S; Garg PK
    EBioMedicine; 2022 Apr; 78():103938. PubMed ID: 35305396
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of immune activation of the COVID vaccines: ChAdOx1, BNT162b2, mRNA-1273, BBIBP-CorV, and Gam-COVID-Vac from serological human samples in Hungary showed higher protection after mRNA-based immunization.
    Fodor E; Olmos Calvo I; Kuten-Pella O; Hamar E; Bukva M; Madár Á; Hornyák I; Hinsenkamp A; Hetényi R; Földes F; Brigitta Z; Jakab F; Kemenesi G; Lacza Z
    Eur Rev Med Pharmacol Sci; 2022 Jul; 26(14):5297-5306. PubMed ID: 35916830
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of SARS-CoV-2 variant protein microarray for profiling humoral immunity in vaccinated subjects.
    Ho TS; Du PX; Su WY; Santos HM; Lin YL; Chou YY; Keskin BB; Pau CH; Syu GD
    Biosens Bioelectron; 2022 May; 204():114067. PubMed ID: 35168024
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.